Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramlintide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 known ✓ | O60894 | 1/20 | 1.00 |
| ▸ | RAMP2 known ✓ | O60895 | 1/20 | 1.00 |
| ▸ | RAMP3 known ✓ | O60896 | 1/20 | 1.00 |
| ▸ | CALCR known ✓ | P30988 | 1/20 | 1.00 |
| ▸ | CALCRL | Q16602 | 1/20 | 1.00 |
| ▸ | NPY2R | P49146 | 12/20 | 0.64 |
| ▸ | PRLHR | P49683 | 5/20 | 0.62 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramlintide SCHEMBL29354060 | 0.99 | RAMP1 (0.99) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL30078470 | 0.95 | RAMP1 (0.91) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Davalintide SCHEMBL29377013 | 0.92 | RAMP1 (0.85) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL31692974 | 0.90 | RAMP1 (0.82) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL374892 | 0.88 | RAMP1 (0.78) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Davalintide SCHEMBL29533482 | 0.87 | RAMP1 (0.77) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL2905167 | 0.87 | CALCR (0.76) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29854921 | 0.87 | CALCR (0.77) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Amylin SCHEMBL29351499 | 0.86 | RAMP1 (0.75) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29720295 | 0.85 | CALCR (0.73) | RAMP1RAMP2RAMP3CALCRCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 944 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107515-A1 | INCRETIN HORMONE COMPOSITIONS AND METHODS USING SAME | DIASOME PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4731243-A2 | IN SITU THERAPEUTIC PRODUCTION: METHODS AND COMPOSITIONS | William Marsh Rice University (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | claimed |
| US-12582607-B2 | Implantable medical devices for extended release of therapeutic agents | NANO PRECISION MEDICAL, INC. (US) | 2026-03-24 | — | — | US | claimed |
| EP-3608338-B1 | HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR | REGENERON PHARMA (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4071173-A1 | ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR | Regeneron Pharmaceuticals, Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| US-20220249505-A1 | APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF | RED MOUNTAIN HOLDINGS, LLC (US) | 2022-08-11 | — | — | US | claimed |
| WO-2022164738-A1 | AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE | INSULET CORPORATION (US) | 2022-08-04 | — | — | WO | claimed |
| US-20220240847-A1 | AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE | MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT | 2022-08-04 | — | — | US | claimed |
| US-20220242919-A1 | METHODS OF PRODUCING GLYCOSYLATED PROTEINS | LIMMATECH BIOLOGICS AG (CH) | 2022-08-04 | — | — | US | claimed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | claimed |
| WO-2022065618-A1 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 위바이오트리 | 2022-03-31 | — | — | WO | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3658115-B1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR | ADOCIA (FR) | 2022-02-23 | — | — | EP | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582607-B2 | Implantable medical devices for extended release of therapeutic agents | SLC11A2, LPO, SLC6A6 | RAMP1 1511/4885RAMP2 1229/4885RAMP3 1794/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | RAMP1 1070/4885RAMP2 934/4885RAMP3 958/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | RAMP1 1160/4885RAMP2 1266/4885RAMP3 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.